01LENZ Therapeutics reported Q2 2026 earnings per share of -$1.02, beating the consensus estimate of -$1.10 by $0.08, and revenue of $5.5M exceeded the estimate of $2.3M.
02The company's stock trades at $5.21 with a market capitalization of $684.1M following the earnings release.
03LENZ has shown sequential improvement in losses, with Q2 EPS of -$1.02 compared to Q1's -$1.32 and Q4's -$1.16, though the company remains unprofitable.
04The earnings beat represents a 7.3% positive surprise on EPS, contrasting with negative surprises in the prior two quarters (-22.2% in Q1 and -27.5% in Q4).
Earnings Results
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly earnings results on August 11, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-1.02, beating the consensus estimate of $-1.10 by $0.08 per share. Revenue came in at $5.5M, beating the estimate of $2.3M.
Company Overview
LENZ Therapeutics's stock moved following the earnings release. The stock currently trades at $5.21 with a market capitalization of $684.1M.
LENZ Therapeutics's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking LENZ Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.